PFE Pfizer
- 27.810
- +0.110+0.40%
- 27.890
- +0.080+0.29%
Pfizer News
Big Bank Ratings | Damo: Raising Pfizer's target price to $29 and is cautiously optimistic about this year's outlook
Glonghui, May 6 | Morgan Stanley released a report stating that Pfizer's first-quarter results exceeded expectations and reiterated that its revenue guidance for this year ranged from 58.5 billion to 61.5 billion US dollars (median of 59.5 billion US dollars), compared to the bank's latest expectations and market expectations of 61.3 billion US dollars and 59.9 billion US dollars, respectively. The company also raised its earnings per share forecast guide for this year from 2.05 to 2.25 US dollars to 2.15 to 2.35 US dollars (median of 2.25 US dollars), indicating that it is confident in the cost restructuring plan and basic business. As for the bank's latest forecast and market expectations, they are 2.57 and 2.21 US dollars, respectively. The line quoted Hui
Goldman's Top 50 Weak Balance Sheet Stocks
Goldman Sachs analysts listed 50 stocks constituents of their “weak balance sheet” basket.
16 Out of 24 Health Care Companies Beat Topline Numbers This Week- Earnings Scorecard
Pfizer Inc. Just Beat EPS By 61%: Here's What Analysts Think Will Happen Next
Pfizer Inc. (NYSE:PFE) defied analyst predictions to release its quarterly results, which were ahead of market expectations. The company beat forecasts, with revenue of US$15b, some 6.9% above es
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
VYNDAMAX (Tafamidis) PBS-listed for Adult Patients With Wild-type or Hereditary Transthyretin Amyloid Cardiomyopathy (ATTR-CM) With New York Heart Association (NYHA) Class I-II Heart Failure
Pfizer Options Spot-On: On May 3rd, 175.29K Contracts Were Traded, With 3.31 Million Open Interest
On May 3rd ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 175.29K options for the day, of which put options accounted for 42.48% of the total transactions, and call op
Vanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Amgen Stock Rallies 13% on GLP-1 Weight-loss Drug Update
NHS to Provide Pfizer's Voxelotor to Treat Sickle Cell Disease
Pfizer Options Spot-On: On May 2nd, 345.72K Contracts Were Traded, With 3.32 Million Open Interest
On May 2nd ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 345.72K options for the day, of which put options accounted for 46.28% of the total transactions, and call op
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
AM Best Affirms Credit Ratings of Blue Whale Re Ltd.
AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
Pfizer Inc (NYSE:PFE) reported first-quarter earnings Wednesday with adjusted EPS of 82 cents. That's down 33% year-over-year, beating the consensus of 54 cents.The New York-based company witnessed a
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Pfizer Price Target Raised to $29.00/Share From $28.00 by Morgan Stanley
Pfizer Price Target Raised to $29.00/Share From $28.00 by Morgan Stanley
Pfizer Is Maintained at Equal-Weight by Morgan Stanley
Pfizer Is Maintained at Equal-Weight by Morgan Stanley
Pfizer Shares Are Trading Higher on Continued Strength After the Company, on Wednesday, Reported Better-than-expected Q1 Financial Results. Josh Brown, on CNBC, Made a Bullish Call on the Stock.
Pfizer Shares Are Trading Higher on Continued Strength After the Company, on Wednesday, Reported Better-than-expected Q1 Financial Results. Josh Brown, on CNBC, Made a Bullish Call on the Stock.
Analysis
Price Target
No Data
